The Markets, Stimulus and COVID-19 Treatment Optimism, IBM Spin-Off, and M&A
Carl Quintanilla, Jim Cramer and David Faber discussed an upbeat morning for stocks, rising on hopes Congress will approve a stimulus package -- with President Trump saying that aid talks are beginning to work out. News on coronavirus treatments also adding to positive sentiment: Regeneron and Lilly shares among the gainers as both companies have requested that the FDA authorize their COVID-19 antibody cocktails for emergency use. The anchors also interviewed IBM CEO Arvind Krishna and Executive Chairman Ginni Rometty about the company's plan to spin off its I-T infrastructure unit and what that move would mean for the Dow component's cloud strategy. Also in focus: Morgan Stanley's deal to acquire Eaton Vance for $7-billion in cash and stock.
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Carl Quintanilla, Jim Cramer and David Faber discussed an upbeat morning for stocks, rising on hopes Congress will approve a stimulus package -- with President Trump saying that aid talks are beginning to work out. News on coronavirus treatments also adding to positive sentiment: Regeneron and Lilly shares among the gainers as both companies have requested that the FDA authorize their COVID-19 antibody cocktails for emergency use. The anchors also interviewed IBM CEO Arvind Krishna and Executive Chairman Ginni Rometty about the company's plan to spin off its I-T infrastructure unit and what that move would mean for the Dow component's cloud strategy. Also in focus: Morgan Stanley's deal to acquire Eaton Vance for $7-billion in cash and stock.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.